share_log

HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $6 Price Target

Benzinga ·  Jul 20, 2023 06:40

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spero Therapeutics (NASDAQ:SPRO) with a Buy and maintains $6 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment